Clinical Trials
2 trialsNCT02767804 2025-10-14
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Xcovery Holdings, Inc.
Phase 3 Active not recruiting
NCT05341583 2024-08-23
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 3 Recruiting